NeoGenomics' PanTracer LBx Receives Medicare Coverage

Expanded access to comprehensive liquid biopsy profiling for cancer patients

Mar. 16, 2026 at 11:05am

Got story updates? Submit your updates here. ›

NeoGenomics, a leading provider of oncology diagnostic solutions, announced that its PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostics Services Program. This decision will enable Medicare patients to receive coverage for the blood-based comprehensive genomic profiling (CGP) test, which is designed to support therapy selection and clinical trial enrollment in patients with advanced solid tumors.

Why it matters

This coverage decision reinforces the clinical value of liquid biopsy and enables physicians to deliver timely, personalized treatment strategies for their patients. It supports broader clinical adoption, reinforces NeoGenomics' position in precision oncology, and underscores the real-world utility of liquid biopsy in guiding patient care.

The details

The PanTracer LBx test evaluates more than 500 genes, including MSI and bTMB, and can be ordered as a standalone test, as a reflex when tissue testing is insufficient, or concurrently with tissue analysis. The test is performed in NeoGenomics' CLIA-certified laboratory in California and has a seven-day turnaround time, providing actionable biomarker information from a simple blood draw.

  • The PanTracer LBx test received coverage from the Centers for Medicare & Medicaid Services' Molecular Diagnostics Services Program on March 16, 2026.

The players

NeoGenomics, Inc.

A leading provider of oncology diagnostic solutions that enable precision medicine.

Centers for Medicare & Medicaid Services (CMS)

The federal agency that administers the Medicare program and works in partnership with state governments to administer Medicaid.

Tony Zook

Chief Executive Officer of NeoGenomics.

Got photos? Submit your photos here. ›

What they’re saying

“Securing Medicare coverage for PanTracer LBx represents a significant milestone in making precision oncology more accessible, particularly for those choosing treatment in the community setting.”

— Tony Zook, Chief Executive Officer of NeoGenomics (Business Wire)

What’s next

The coverage decision by CMS is expected to enable broader clinical adoption of the PanTracer LBx test, reinforcing NeoGenomics' position in precision oncology and underscoring the real-world utility of liquid biopsy in guiding patient care.

The takeaway

This coverage decision from CMS will improve access to comprehensive liquid biopsy profiling for Medicare patients with advanced solid tumors, allowing physicians to deliver more personalized treatment strategies and supporting the broader clinical adoption of this innovative diagnostic tool.